Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases

NCT04349566 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2022-10-27

No results posted yet for this study

Summary

The purpose of the study is to explore the biomarker Fast Troponins response to exercise in patients with Becker muscular dystrophy, Limb-girdle muscular dystrophy and McArdle disease

Conditions

  • Becker Muscular Dystrophy
  • McArdle Disease
  • Limb-Girdle Muscular Dystrophy Type 2

Sponsors & Collaborators

  • Edgewise Therapeutics, Inc.

    collaborator INDUSTRY
  • Mads Peter Godtfeldt Stemmerik

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-12-20
Completion
2021-12-20

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04349566 on ClinicalTrials.gov